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Abstract
Objectives: Ulcerative colitis (UC) is a relapsing inflammatory disorder of unconfirmed aetiology, variable severity and
clinical course, characterised by progressive histological inflammation and with elevation of eicosanoids which have a
known pathophysiological role in inflammation. Therapeutic interventions targetting eicosanoids (5-aminosalicylates (ASA))
are effective first line and adjunctive treatments in mild-moderate UC for achieving and sustaining clinical remission.
However, the variable clinical response to 5-ASA and frequent deterioration in response to cyclo-oxygenase (COX) inhibitors,
has prompted an in depth simultaneous evaluation of multiple lipid mediators (including eicosanoids) within the
inflammatory milieu in UC. We hypothesised that severity of inflammation is associated with alteration of lipid mediators, in
relapsing UC.
Design: Study was case-control design. Mucosal lipid mediators were determined by LC-MS/MS lipidomics analysis on
mucosal biopsies taken from patients attending outpatients with relapsing UC. Univariate and multivariate statistical
analyses were used to investigate the association of mucosal lipid mediators, with the disease state and severity graded
histologically.
Results: Levels of PGE2, PGD2, TXB2, 5-HETE, 11-HETE, 12-HETE and 15-HETE are significantly elevated in inflamed mucosa
and correlate with severity of inflammation, determined using validated histological scoring systems.
Conclusions: Our approach of capturing inflammatory mediator signature at different stages of UC by combining
comprehensive lipidomics analysis and computational modelling could be used to classify and predict mild-moderate
inflammation; however, predictive index is diminished in severe inflammation. This new technical approach could be
developed to tailor drug treatments to patients with active UC, based on the mucosal lipid mediator profile.
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Introduction
Ulcerative colitis (UC) is a chronic, relapsing intestinal
inflammatory disorder of the colonic mucosa, with variable
distribution but limited to the distal bowel (distal colitis and
proctitis) in 60% of cases [1]. In distal colitis there is commonly a
clear demarcation between inflamed and non-inflamed tissues that
demonstrate contrasting patterns of immunomodulator release [2].
Despite advances in medical treatments, including biologics that
target cytokine-led inflammatory responses for severe disease, long
term control of UC is variable with available therapeutic
interventions [3–5], with 57% of all patients following a relapsing
and remitting clinical course [6,7]. In mild to moderate relapsing
disease only, a limited therapeutic repertoire is available to
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patients principally as oral or topical 5-aminosalicylic acid (5-ASA)
and corticosteroids.
Mucosal inflammation in UC is characterised by an infiltrate of
neutrophils, plasma cells and eosinophils, which correlate with
disease severity and are predictors of disease relapse [8–10]. It is
proposed that lipid inflammatory mediators, including eicosanoids,
which are rapidly and locally formed and degraded in-situ,
promote neutrophil chemotaxis [11,12], a pivotal step in the
inflammatory cascade. Furthermore, mucosal inflammation in UC
responds to therapeutic interventions that target eicosanoid
production such as 5-ASA [13,14]. However, the understanding
of both the pathophysiology of UC and pharmacotherapeutic
effects of 5-ASA is limited, which has inhibited the development of
new therapeutic interventions.
Eicosanoids are a family of lipid mediators, derived from
polyunsaturated fatty acids (PUFA) enzymatically and oxidatively
[15]. Previous studies have demonstrated up regulation of the
eicosanoid biosynthetic enzymes cyclooxygenase (COX)-1, COX-
2, and 5-lipoxygenase (LOX) in active UC [16] and elevation of
both prostaglandin (PG)E2 [17] and leukotriene (LT)B4 [18]
derived from the n-6 PUFA arachidonic acid (AA) in UC.
Eicosanoids may also derive from the n-3 PUFA eicosapentaenoic
acid (EPA); EPA-derived eicosanoids include PGE3 and LTB5.
Frequently the mediators produced from AA and EPA differ in
their inflammatory potency [19,20]. However, studies attempting
to alter eicosanoid production through dietary modification of
mucosal lipid profile in active UC have been disappointing, with
only modest effects on relapse rates and corticosteroid require-
ment, despite sound experimental results in healthy volunteers
[21,22].
The aims of this study were to investigate the levels of PUFA-
derived lipid mediators within inflamed colonic mucosa in mild to
moderate UC, to determine their relationship to endoscopic and
histological changes, to identify mediators that have not previously
been considered possible contributors to the inflammatory cascade
in UC, and, as a result, to identify potential targets for
intervention. The investigation of patients with distal colitis
enabled comparative assessment of endoscopically normal and
inflamed tissues as a model, as previously described [2].
Materials and Methods
2.1. Subjects and Mucosal Biopsy
This was a case-control of UC patients identified during
attendance at gastroenterology outpatients’ clinics at the Royal
Haslar and St Mary’s Hospital, Portsmouth Hospitals NHS Trust
between November 2008 and July 2009. The diagnosis of UC was
based on endoscopic and histological investigation [23,24]. All
recruited patients underwent a questionnaire-based assessment of
their demographic characteristics, previous and presenting med-
ical history, and UC history. Clinical disease activity was
determined using the UCDAI score [25].
Patients with clinical evidence of active disease underwent
unprepared flexible sigmoidoscopy examination as part of their
routine clinical management. An endoscopy assessment was
undertaken by two endoscopists blinded to the patient’s clinical
presentation using a validated scoring tool to stratify patients into
active or quiescent UC with photographic evidence obtained, and
to identify demarcation of inflamed with apparently non-inflamed
mucosa. Biopsies were taken according to a standard protocol,
specifically developed to measure target analytes in adjacent areas
of inflamed and non-inflamed mucosa in patients with active distal
UC. Flexible sigmoidoscopy in patients with active distal UC to
above visual demarcation of normal mucosa was followed by grab
biopsy, obtained using flexible biopsy forceps, in endoscopically
inflamed and non-inflamed areas. All mucosal biopsy samples
were snap-frozen and stored in liquid nitrogen until use.
Exclusion criteria were age less than 16 or greater than 80 years;
refusal to undergo endoscopic evaluation; diagnosis of colitis of
alternative aetiology; concurrent use of non-steroidal anti-inflam-
matory medication; inability to provide consent.
The study was approved by the Isle of Wight, Portsmouth and
South East Hampshire research ethics committee (project number
08/H0501/82). All subjects provided written informed consent.
2.2. Analysis of Lipid Mediators
2.2.1. Reagents and standards. PGE2, PGD2, thrombox-
ane (TX)B2, 6-keto-PGF1a, PGB2-d4, 13,14-dihydro-15-keto-
PGE2, 9-hydroxy-10(E),12(Z)-octadecadienoic acid (9-HODE),
13-hydroxy-9(Z),11(E)-octadecadienoic acid (13-HODE), 5-hy-
droxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic acid (5-HETE), 8-hy-
droxy-5(Z),9(E),11(Z),14(Z)-eicosatetraenoic acid (8-HETE), 11-
hydroxy-5(Z),8(Z),12(E),14(Z)-eicosatetraenoic acid (11-HETE),
12(S)-hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic-
5,6,8,9,11,12,14,15-d8 acid (12-HETE-d8), 9-hydroxy-
5(Z),7(E),11(Z),14(Z)-eicosatetraenoic acid (9-HETE), 15-hy-
droxy-5(Z),8(Z),11(Z),13(E)-eicosatetraenoic acid (15-HETE), 12-
hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid (12-HETE)
and LTB4 standards were purchased from Cayman Chemicals
(Ann Arbor, MI). HPLC-grade acetonitrile, ethanol, methanol,
hexane, and hydrochloric acid were from Fisher Chemicals
(Loughborough, UK), HPLC-grade acetic acid and methyl
formate from Sigma (Dorset, UK), and solid-phase extraction
(SPE) cartridges (C18-E, 500 mg, 6 mL) from Phenomenex
(Macclesfield, UK).
2.2.2. Solid phase extraction. Extraction of lipid mediators
was carried out according to a previously described method [26].
In summary, mucosal biopsy samples (approximately 3–5 mg)
were weighed on thawing and immediately transferred to 15% ice-
cold methanol in water (3 mL) and homogenised using Wheaton
Tapered tissue grinders. Internal standards (PGE2-d4 and 12-
HETE-d8 (20 ng)) were added to each sample. The samples were
acidified with 0.05 M hydrochloric acid to pH 3.0 and immedi-
ately applied to SPE cartridges that had been preconditioned with
20 mL of methanol, followed by 20 mL of water. The cartridges
were then washed with 20 mL of 15% (v/v) methanol, 20 mL of
water, and 10 mL of hexane. Finally, the lipid mediators were
eluted with 10 mL of methyl formate. The organic solvent was
evaporated using a fine stream of nitrogen, the solute reconstituted
in ethanol (100 mL), and the final solution stored at 220uC until
analysis within 48 hours.
2.2.3. Lipidomics analysis. Data-dependent LC-MS/MS
lipidomics analysis was performed using Accela UHPLC system
(Thermo Scientific, Hemel Hempstead, UK) coupled to LTQ
Velos (Thermo, Hemel Hempstead, UK) linear ion trap (LIT)-
orbitrap as described previously [26]. The analysis on the orbitrap
instrument was carried out using heated electrospray ionization (h-
ESI) in negative ion mode at sheath, auxiliary and sweep gas flows
of 24, 2 and 1, respectively [26]. The capillary and source heater
temperatures were set to 275uC and 50uC, respectively. The ion
spray voltage was adjusted to 4000 V. MS/MS spectra, along with
retention times and isotope distribution patterns from the MS
spectra were used to identify lipid mediators in mucosal biopsy
samples. The identified metabolites were quantified using Acquity
UPLC (Waters, Hertsfordshire, UK) systems coupled to QTRAP
4000 (AB Sciex, Concord, ON) quadrupole2linear ion trap
(QqLIT) mass spectrometers as described previously [26]. The
lipid mediators were separated on a C18 reversed-phase (RP) LC
Eicosanoids and Lipid Mediators in UC
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e76532
column (Phenomenex Luna, 3 mm particles, 15062 mm) using a
linear mobile phase gradient (A, 0.02% glacial acetic acid in water;
B, 0.02% glacial acetic acid in acetonitrile) at 0.5 mL/min. The
starting conditions consisted of 30% B and then increased to 90%
B over 14 min and finally returned to the initial conditions for
2 min to allow equilibration.
2.3. Histological Analysis
Assessment was by a histopathologist blinded to patients’
identities and clinical data on paraffin embedded serial haema-
toxylin and eosin (H&E) stained sections using a validated
histopathological scoring tool [24] (0, normal; 1, mild oedema
and inflammation in lamina propria; 2, crypt abscess formation
and inflammation in lamina propria; 3, more severe inflammation
with destructive crypt abscesses +/2granulomata; 4, more severe
inflammation with active ulceration) (Figure 1).
2.4. Statistical Analysis
Lipid mediator concentration is expressed as pg/mg tissue.
Unblinded bioinformatics analysis was carried out following
completion of lipid mediator measurement on blinded samples.
2.4.1. Univariate statistical analysis. Wilcoxon’s Signed
Rank Test was used as a non-parametric pair-wise univariate
testing method at a confidence interval of 97.5%. Analysis was
carried out using custom workflows written in the programming
language R. Metabolites with a value of p,0.05 were regarded as
significantly different. Subgroup analysis to investigate the effect of
no 5-ASA or corticosteroid (n18) use was undertaken and
metabolites with a value of p,0.05 were regarded as significantly
different.
2.4.2. Multivariate statistical analysis. Since univariate
statistical testing is unable to characterise the interrelationship of
variables, multivariate statistical analysis was performed to
examine association with disease state (inflamed/non-inflamed)
as well as disease severity assessed histologically using the Gomes
scoring system. Similar to the paired univariate testing, we were
primarily interested in the within-subject variation and therefore
performed a variation split prior to analysis (to remove between
subject variation), a technique developed in the context of multi-
level multivariate data analysis [27,28].
On the remaining within-subject variation data we performed
Principal Component Analysis (PCA) for unsupervised analysis,
followed by (Orthogonal) Partial Least Squares (PLS) Analysis for
the association with disease severity assessed histologically, and
(Orthogonal) Partial Least Squares Discriminant Analysis (PLS-
DA) for the investigation of the disease state (inflamed/non-
inflamed). Variation splitting was implemented using the pro-
gramming language R, Partial Least Squares Approaches were
performed using R as well as SIMCA-P 12.01 (Umetrics, AB,
Sweden).
Results
3.1. Subjects
Patients with active UC (n 69) were recruited; biopsy data sets of
‘paired’ macroscopically inflamed and non-inflamed tissues were
available in 54 UC patients. Baseline characteristics of patients are
shown in Table 1.
3.2. Lipid Mediators: Univariate Analysis
Mucosal biopsies from inflamed and non-inflamed mucosa were
screened for all PUFA-derived bioactive lipids and deactivated
metabolites. Reported metabolites included eicosanoids derived
from AA (TXB2, 6-keto-PGF1a, PGE2, PGD2, 5-HETE, 15-
HETE, 12-HETE and 11-HETE) and linoleic acid (LA) (13-
HODE, 13-oxo-ODE, 9-HODE). EPA-derived eicosanoids (5-
hydroxy-eicosapentaenoic acid (HEPE), 12-HEPE, 15-HEPE)
were excluded from analysis as their concentration was below
the limit of quantification. Neither PGE3 nor LTB5 were detected.
3.2.1. LOX-related lipid mediators. 5-HETE (p,0.001)
and 15-HETE (p,0.001) concentrations in inflamed mucosa were
significantly higher than in adjacent non-inflamed mucosa
(Table 2, Figure 2). Other 5-LOX metabolites of AA such as
LTB4 and 5-oxo-ETE were inconsistently detected. There were no
significant differences in the concentrations of LA-derived LOX
metabolites such as 9-HODE, 13-HODE and 13-oxo-ODE.
3.2.2. COX-related lipid mediators. PGE2 (p,10
26),
PGD2 (p,0.01) and TXB2 (p,10
26) concentrations in inflamed
mucosa were significantly higher than in adjacent non-inflamed
mucosa (Table 2; Figure 3). There were no other significant
differences in concentration of COX metabolites between non-
inflamed and inflamed mucosa. PGF2a and the deactivated form
of PGE2, 13,14-dihydro-15-keto-PGE2, were only detectable in
50% of the samples and therefore were excluded from analysis.
3.3. Lipid Mediators: Multivariate Analysis
The principal component analysis (PCA), an unsupervised
multivariate analysis technique, which is driven by the variance
inherent in the data set and has no prior assumption of class
membership, revealed a clear differentiation between inflamed
and endoscopically non-inflamed adjacent mucosal tissue in
patients with distal UC (Figure 4A).
Furthermore, O2-PLSDA, a supervised analysis, was performed
to actively check for differences in the lipid mediator profile
between inflamed and non-inflamed tissue. As expected from the
PCA analysis, the O2PLS-DA model (R2X(cum) = 79%,
R2Y(cum) = 60% and Q2= 60%) was clearly able to differentiate
the two phenotypic groups (Figure 4B). Using the O2PLS-DA
model, 87.5% of inflamed tissue was correctly identified as
inflamed based upon the lipid mediator profile, while 87.5% of
non-inflamed tissue was correctly identified as non-inflamed.
In order to investigate which metabolites made the greatest
contribution to the separation observed in O2PLS-DA model
(Figure 4B), a variable importance plot was created; PGE2 had
the highest contribution followed by TXB2, 15-HETE, 5-HETE,
12-HETE and 11-HETE, respectively in diminishing magnitude
(Figure 5). This is consistent with the results of the univariate
statistical analysis (Table 2), and demonstrates contribution of 12-
HETE and 11-HETE which were significantly higher (all p,0.05)
in inflamed compared with non-inflamed colonic mucosa in the
univariate analysis. PGD2 was excluded from this multivariate
analysis as it was detected in ,85% of samples.
3.4. Association between Lipid Mediators and Clinical
Grading
O2-PLS Analysis was performed in order to examine the
relationship between lipid mediator concentration and histological
grading (Figure 6). The model (R2X(cum) = 86%,
R2Y(cum) = 57% and Q2= 51%) was able to separate non-
inflamed from inflamed tissue; however within the inflamed tissue
there was an overlap between histological grades (Figure 6A).
Although it was possible to predict mild-moderate inflammation
(grade 1 and 2) from the lipid mediator profile (Figure 6B), highly
inflamed tissue (grade 3), failed to fit into this model; however this
latter group contained 5 subjects only.
In order to investigate which metabolites had the greatest
contribution to the separation observed in the O2PLS model, a
variable importance plot was created; PGE2 showed the highest
Eicosanoids and Lipid Mediators in UC
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impact followed by 5-HETE, 15-HETE, TXB2, 12-HETE and
11-HETE, respectively in diminishing magnitude (Figure 7).
3.5. 5-ASA and Corticosteroid Naive Patients
Subgroup analysis within ‘paired’ inflamed and non-inflamed
mucosa from 18 UC patients (age 45.3 years; male n 10 [55%],
female n 8 [45%]) not recently (within 3 months) on 5-ASA or
corticosteroid treatment was carried out. Analysis of lipid
mediators demonstrated that PGE2, PGD2, TXB2 and 15-HETE
(all p,0.05) were higher in inflamed than non-inflamed mucosa;
however, the other measured lipid mediators were not significantly
different (Table 3). The results within the subgroup analysis are
comparable to the total group univariate analysis.
Figure 1. Gomes histological classification of UC. 1A: Gomes 0 (normal); 1B: Gomes 1 (mild oedema and inflammation in lamina propria with
cryptitis); 1C: Gomes 2 (crypt abscess formation and inflammation); 1D: Gomes 3 (destructive crypt abscesses +/2 granulomata); 1E–F: Gomes 4
(active ulceration and formation of granulation tissue with neoangiogenesis).
doi:10.1371/journal.pone.0076532.g001
Eicosanoids and Lipid Mediators in UC
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e76532
3.6. Controls
Lipid mediator levels (TXB2 – 38.8 [27.5–51.6]; 6-keto-PGF1a –
36.1 [27.8–49.5]; PGE2 – 14.9 [7.1–24.1]; PGD2 – 9.9 [4.0–17.7];
9-HODE – 38.3 [20.0–55.6]; 5-HETE – 6.2 [3.0–12.4]; 15-
HETE – 19.1 [10.7–32.4]; 13-oxo-ODE – 21.6 [14.8–41.3]; 13-
HODE – 55.4 [29.8–84.2]; 12-HETE – 9.1 [5.5–16.5]; 11-HETE
– 9.4 [7.0–15.7]) were measured in normal colorectal mucosa
obtained from a group of 42 control patients undergoing routine
flexible sigmoidoscopy examination.
Discussion
In the current study we demonstrate differences in the
concentration of a number of lipid mediators between inflamed
and non-inflamed areas of the colonic mucosa from patients with
UC. The findings suggest that inflammation of the colonic mucosa
in UC is associated with significant elevation in concentrations of
PGE2, PGD2, TXB2, 5-HETE, 15-HETE, 12-HETE and 11-
HETE, but not of other measured lipid mediators (Table 2). In
addition, the profile of these same lipid mediators correlates with
severity of inflammation measured histologically. To our knowl-
edge this is the first study to simultaneously demonstrate
comprehensive alterations in multiple lipid mediators, which
correlate proportionately to the degree of histological inflamma-
tion in patients with UC. This is also in agreement with previous
studies that showed upregulation in eicosanoids, which correlate
proportionately to the degree of histological inflammation in
patients with UC; however, previous studies have been limited to
investigation of selected enzymatic pathways (COX-2 and 5-LOX)
in UC[16–18,29–32].
Several of the identified inflammatory mediators have immu-
nomodulatory roles as demonstrated either in cohorts of inflam-
matory bowel disease (IBD) patients or in experimental studies.
For example, PGE2 is produced via COX-1 and COX-2 within
the AA cascade and has pro-inflammatory (via cytokine induction
pathways) and anti-inflammatory (via lipoxin induction) effects
[33,34]. PGE2 has been consistently demonstrated in previous
studies to be elevated in inflamed colonic mucosa in UC [17]. 12-
HETE is produced via 12-LOX within the AA cascade and is
known to exert chemotactic effects on neutrophils [35,36]. 5-
HETE and LTB4 are both products of 5-LOX within the AA
cascade; neutrophils contain large quantities of 5-LOX and are
able to produce abundant 5-HETE and LTB4 [37,38]. 5-HETE is
a potent activator of eosinophils and neutrophils via 5-oxo-
6,8,11,14-eicosatetraenoic acid (5-oxo-ETE). 5-HETE and 12-
HETE were readily detected in inflamed mucosal samples.
Table 1. Baseline characteristics of patients with active UC.
Category Subcategory Result
Sex [n(%)] Male 26 (48)
Female 28 (52)
Age [yr]‘ 44.461.8
CRP [mg/l]‘ 7.061.1
BMI [kg/m2]‘ 27.560.8
Disease Distribution [n(%)] Proctitis 32 (60)
Distal 16 (30)
Left sided 3 (6)
Extensive 3 (6)
Disease Longevity [yr(%)] 0–5 22 (41)
5–10 15 (28)
10–15 6 (11)
15–20 3 (6)
.20 7 (13)
unknown 1 (2)
Current drug history [n(%)] 5-ASA 32 (60)
Corticosteroids 14 (26)
Thiopurines 8 (15)
Methotrexate 1 (2)
Cyclosporine 1 (2)
Disease activity-UCDAI*,‘ 4.860.4
Disease activity-endoscopic
score [n(%)]¥
1 36 (67)
2 13 (24)
3 5 (9)
Disease activity-histological
score [n(%)]J
0 8 (15)
1 24 (44)
2 11 (20)
3 8 (15)
4 3 (6)
Smoking history [n(%)] yes 6 (11)
no 48 (89)
*UCDAI-ulcerative colitis disease activity index [59] (Daily stool frequency
[0 = normal; 1 = 1–2 above normal; 2 = 3–4 above normal; 3 =.4 above
normal]+Rectal bleeding [0 = none; 1 = streaks of blood; 2 = obvious blood;
3 =mostly blood]+Sutherland score [see below]+Physicians global assessment
[0 = normal; 1 =mild; 2 =moderate; 3 = severe]).
¥Sutherland endoscopic scoring tool [25] (0 = normal; 1 =mild friability;
2 =moderate friability, bleeding on contact; 3 = exudation, spontaneous
haemorrhage).
JGomes Histological score [24] (0 = normal, 1 =mild oedema and inflammation
in lamina propria; 2 = crypt abscess formation and inflammation in lamina
propria; 3 =more severe inflammation with destructive crypt abscesses +/
2granulomata; 4 =more severe inflammation with active ulceration).
‘mean 6 SEM.
doi:10.1371/journal.pone.0076532.t001
Table 2. Lipid mediator concentrations (pg/mg tissue) in
colonic mucosa (inflamed and non-inflamed) in UC patients.
Paired data
Lipid mediator InflamedJ Non-inflamedJ p-value*
TXB2 46.2 (27.2–70.7) 32.2 (20.6–41.7) ,10
26
6-keto-PGF1a 34.9 (17.9–51.4) 29.5 (14.8–48.4) 0.201
PGE2 24.1 (13.4–56.2) 9.0 (4.8–15.3) ,10
26
PGD2 13.9 (5.9–21.9) 12.1 (2.5–16.4) 0.001
9-HODE 27.4 (20.1–45.7) 33.9 (19.5–42.3) 0.368
5-HETE 9.4 (4.0–23.2) 5.3 (3.2–11.5) ,1023
15-HETE 39.2 (26.0–97.0) 33.4 (23.4–48.5) ,1023
13-oxo-ODE 30.1 (19.1–42.0) 31.0 (21.6–42.2) 0.320
13-HODE 57.1 (30.9–91.4) 67.1 (31.9–88.8) 0.650
12-HETE 13.5 (7.5–21.4) 12.7 (7.1–16.6) 0.021
11-HETE 11.7 (10.2–18.1) 10.5 (7.3–14.7) 0.028
JData are median 6 IQR.
*Wilcoxon signed rank pair analysis.
doi:10.1371/journal.pone.0076532.t002
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LTB4 is a potent chemoattractant for neutrophils and other
leukcoytes [39]; however, LTB4 was not consistently demonstrated
in our samples. LTB4 is reported to be elevated in inflamed
mucosa in UC; however, critical review of published methods
reveals that levels were measured in in vivo rectal dialysates or
mucosal explants, which would have led to neutrophil activation
inadvertently or by design [40–48]. The presented method
controls for altered lipid mediator production induced by
experimental methods. The lack of consistent demonstration of
LTB4 in the context of elevated 5-HETE (both 5-HPETE
derivatives) may suggest that the bioactive concentration of
LTB4 is below the detectable limit, or that it is rapidly metabolised
in inflamed mucosal samples. An alternative explanation, that 5-
HETE is the predominant 5-LOX derived chemoattractant lipid
Figure 2. Median and interquartile range of LOX-related lipid mediators (pg/mg tissue) in grouped non-inflamed and adjacent
inflamed mucosa with difference plots of paired samples. 2A: 11-HETE; 2B: 12-HETE; 2C: 15-HETE; 2D: 5-HETE.
doi:10.1371/journal.pone.0076532.g002
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mediator, or that PGE2 mediated inhibition of FLAP (5-
lipoxygenase activating protein) abrogates LTB4 production,
should be considered [49]; however, this was not specifically
tested in our study.
The pro-inflammatory mediator TXB2, a stable derivative of
TXA2 and both AA derivatives via COX-dependent conversion
from PGH2, is elevated in inflamed compared with non-inflamed
mucosa, as has been demonstrated previously [50].
In contrast, PGD2 and its metabolite 15-deoxy D
12,14 PGJ2
exert anti-inflammatory effects [51], and several studies have
suggested a role for PGD2 in resolution of inflammation, reduction
of leukocyte infiltration and healing within the colon[32,52–54].
Consistent with other studies, we observed a significant increase in
Figure 3. Median and interquartile range of COX-related lipid mediators (pg/mg tissue) in grouped non-inflamed and adjacent
inflamed mucosa with difference plots of paired samples. 3A: PGE2; 3B: PGD2; 3C: TXB2.
doi:10.1371/journal.pone.0076532.g003
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the levels of PGD2 in inflamed tissue, although its metabolite 15-
deoxy D12,14 PGJ2 was not detectable in mucosal biopsies.
Sub-group analysis (n 18) of a group of patients not receiving
corticosteroids and 5-ASA confirmed significant differences in
Figure 4. Data separation of inflamed (triangle) and non-inflamed (circle) mucosa based on lipid mediator concentration. 4A: PCA
score plot (unsupervised analysis); 4B: O2PLS-DA plot (supervised analysis).
doi:10.1371/journal.pone.0076532.g004
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PGE2, PGD2, TXB2 and 15-HETE in inflamed mucosa (Table 3),
with no significant differences observed in 5-HETE, 11-HETE
and 12-HETE concentrations in inflamed compared with non-
inflamed mucosa. This may indicate the diminished power to
detect differences in all measured eicosanoids in this group due to
sample size, or possibly a more benign clinical course in this
untreated group.
Using predictive mathematical modelling, we have demonstrat-
ed that the measured lipid mediator profile may be used to predict
presence or absence of histological inflammation with sensitivity,
specificity, and positive predictive and negative predictive values of
87.5%. It was also possible to grade severity of inflammation based
on blinded histological assessment; however, predictive modelling
was less consistent in patients with severe inflammation. This may
be due to the small group of patients (n 5) in this group, or may
suggest that alternative inflammatory mediators become predom-
inant in severe mucosal inflammation.
Eicosanoids and other lipid mediators are generated via
oxidative pathways (COX and LOX) at the cytosolic interface of
the cell membrane. They have pleiotropic effects and biochemical
activity is influenced by the species of PUFA from which they are
derived. In excess of 40 different eicosanoids from PUFA
substrates are recognised. These are derived from obligate dietary
constituents, LA, AA and EPA, but principally from AA due to the
higher membrane content of AA and the lower bioavailability of
EPA. Provision of EPA orally can influence the levels of AA in cell
membranes and reduce pro-inflammatory AA derived lipid
mediators in patients with IBD [55] and in healthy subjects
[56]; although clinical therapeutic efficacy is inconsistently
demonstrated [21,57].
In the current study, although AA-derived lipid mediators
(PGE2, PGD2, TXB2, 5-HETE, 15-HETE, 12-HETE and 11-
HETE) were detectable in inflamed mucosa, EPA-derived
mediators (PGE3, PGD3, TXB3, 5-HEPE, 15-HEPE, 12-HEPE
and 11-HEPE) were not, or were detected at unquantifiable levels.
We previously reported that actively inflamed mucosa in UC is
associated with increased AA and reduced EPA in both the
complex lipid and free fatty acid pools, with a consistently altered
AA/EPA ratio compared with adjacent non-inflamed mucosa, and
that this alteration is despite no significant difference in the level of
dietary intake of PUFA (Pearl et al) [42]. These findings are
consistent and suggest that metabolic alteration of AA production
in inflamed tissue may lead to enhanced substrate availability for
eicosanoid biosynthetic enzymes which are constitutively up
regulated in actively inflamed mucosa, with resulting up regulation
in all classes of eicosanoids, which we have detected.
These findings may be relevant to the failure of dietary
intervention studies with EPA. This may be because EPA and its
lipid mediators including eicosanoids are present at very low levels
in inflamed mucosa, whereas AA and its lipid mediators including
eicosanoids are present at much higher levels. Supplementation
with EPA may not bring about significant rebalancing of the AA/
EPA ratio, which would be required to reduce the levels of AA
derived eicosanoid lipid mediators in inflamed mucosa.
In addition, eicosanoids derived from both COX- and LOX-
related pathways are significantly elevated indicating co-activation
of multiple eicosanoid biosynthetic pathways within the AA
cascade in inflamed mucosa. The role of eicosanoids is further
supported by the known therapeutic effect of 5-ASA drugs, which
act by binding to peroxisome proliferator activated receptor c in
Figure 5. Variable importance plot in O2PLS-DA analysis demonstrates relative contribution of lipid mediators to separation
between inflamed and non-inflamed mucosa. (Fig. 4).
doi:10.1371/journal.pone.0076532.g005
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the colonic epithelium with subsequent suppression of pro-
inflammatory lipid mediator production [18].
Co-activation of multiple synthetic pathways may suggest
redundancy within eicosanoid signalling networks; however, an
alternative explanation is that candidate eicosanoid-receptor
signalling independently stimulates initiation, propagation, reso-
lution and/or suppression stages of inflammation. This is
supported by the observed loss of intestinal eicosanoid homeosta-
sis, as occurs with COX inhibition during non-steroidal anti-
inflammatory drug use, which is associated with an increased risk
of UC relapse in quiescent disease [58]. This is also supported by
detection of pro-inflammatory (PGE2) and anti-inflammatory
(PGD2) lipid mediators within the same tissue matrix, as in the
current study [51].
The role of detected eicosanoids (PGE2, PGD2, TXB2, 5-
HETE, 15-HETE, 12-HETE and 11-HETE) in UC is difficult to
address precisely, as this study was not designed to investigate
changes occurring as a result of therapy, or temporal changes in
mucosal lipid mediators associated with disease activity.
Figure 6. O2PLS model showing computed prediction of disease severity based on lipid mediator profile. 6A: Plot showing O2PLS
regression score plots; 6B: plot showing actual vs. predicted GOMES score based on lipid mediator profile.
doi:10.1371/journal.pone.0076532.g006
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There is therefore emergent evidence that UC is associated with
changes in PUFA profile with elevated AA/EPA ratio suggesting
alteration of production of the eicosanoid substrate AA (Pearl et al)
[42], and with associated elevation of AA-derived eicosanoids
which correlate with grade of histological inflammation.
Further research should focus on the use of predictive modelling
based on mucosal derived lipid mediators to determine if drug
non-responders can be predicted, and to target appropriate
therapy. This would be a unique development in management
of chronic inflammatory disorders.
Additional research could focus on characterization of lipid
mediators biosynthesis during initiation, propagation, resolution
and suppression stages of inflammation, and to relate these to
metabolic activity within the fatty acid biosynthetic cascade. This
would allow a focussed time-course assessment of the role of lipid
mediators during the evolution of inflammation using distal UC as
a model and may inform new targets for development of
therapeutic interventions in UC and inflammatory disorders.
In conclusion, development of new approaches and treatments,
based on selective lipid mediators, may offer new investigative and
therapeutic strategies to target treatment in patients with mild-
moderate chronic active steroid and immunomodulator resistant
UC in whom an organ sacrificing approach via surgical colectomy
is being considered.
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Table 3. Lipid mediator concentrations (pg/mg tissue) in
colonic mucosa (inflamed and non-inflamed) in treatment
naive UC.
Paired data
Lipid mediator InflamedJ Non-inflamedJ p-value*
TXB2 43.4 (27.6–59.3) 28.7 (15.9–48.1) 0.002
6-keto-PGF1a 34.9 (25.2–51.5) 37.9 (5.8–47.4) 0.776
PGE2 27.1 (16.9–42.8) 7.1 (2.4–15.9) ,10
23
PGD2 10.3 (5.4–23.4) 3.8 (2.2–15.4) 0.016
9-HODE 25.2 (15.0–46.8) 30.6 (17.6–55.1) 0.879
5-HETE 14.7 (7.0–23.4) 10.4 (4.6–19.4) 0.191
15-HETE 40.8 (23.3–103.6) 39.1 (13.6–51.0) 0.005
13-oxo-ODE 24.4 (15.1–37.1) 31.0 (13.7–43.6) 0.913
13-HODE 60.8 (28.4–96.0) 67.5 (29.2–95.4) 0.811
12-HETE 14.7 (7.7–25.2) 13.9 (5.3–20.6) 0.133
11-HETE 10.0 (6.7–13.6) 9.1 (5.1–10.7) 0.053
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